We are pleased to share major updates from Avails Medical, Inc., a Propelx portfolio company that is revolutionizing how doctors detect antibiotic resistance, helping hospitals identify the right treatment for patients faster and more accurately.
Here’s how Avails Medical is doing:
• In 2024, Avails received FDA 510(k) clearance for its eQUANT™ system, allowing faster and more reliable antibiotic testing workflows.
• The company signed its first commercial agreement in 2025, marking a major step toward bringing its technology into real-world hospital use.
• Avails began a U.S. pilot trial for its eAST™ rapid AST system to validate real-world performance, showing promising accuracy and reliability.
• The company has attracted strong interest at major diagnostics conferences and continues to expand partnerships with leading research and healthcare institutions.
Led by CEO Oren Knopfmacher, PhD, and supported by top investors including Omron Ventures Co., Ltd., Analog Devices, and StartX Fund, Avails is establishing itself as a leader in rapid diagnostics innovation.
With strong science, growing commercial traction, and a clear mission to combat antibiotic resistance, Avails Medical is on an exciting growth path toward large-scale clinical and global impact.
We are proud to have invested in Avails Medical’s journey and applaud the team for their innovation and progress.
Register on Propelx to explore new investment opportunities: https://www.propelx.com/
